GlassScriptPhysician profile
Matthew B Carroll
NPI 1124247341
$56,077.63
in general payments reported to CMS, 2019-2025
42 companies · $3,675 in 2025
The $3,675 reported for 2025 was more than what 81% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $4,499 · 2021: $3,470 · 2022: $3,274 · 2023: $3,497 · 2024: $3,665 · 2025: $3,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,479 · Consulting Fee: $995 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $250 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,479.23 |
| Consulting Fee | $995.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $250.00 |
| Education | $113.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $20,819.21 | 2019-2021 | |
| Gilead Sciences, INC. | $6,449.15 | 2019 | |
| Abbvie INC. | $4,728.37 | 2019-2025 | Rinvoq, Skyrizi |
| Horizon Therapeutics Plc | $4,690.01 | 2019-2022 | |
| Amgen INC. | $4,218.98 | 2019-2025 | Tavneos, Enbrel, Otezla |
| Ucb, INC. | $2,311.18 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,807.39 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,649.49 | 2019-2024 | Ofev, Cyltezo |
| Novartis Pharmaceuticals Corporation | $1,427.65 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,012.87 | 2019-2025 | Orencia, Sotyktu |
| Glaxosmithkline, LLC. | $915.35 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $883.73 | 2019-2025 | Tremfya, Simponi Aria |
| Lilly USA, LLC | $861.16 | 2019-2025 | Taltz, Ebglyss |
| Alexion Pharmaceuticals, INC. | $508.79 | 2019-2025 | Strensiq |
| Sobi, INC | $358.76 | 2020-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.